

ASX ANNOUNCEMENT

MINIMUM HOLDING BUY-BACK COMPLETED

SYDNEY, Thursday, 23 May 2019: Cellmid Limited (ASX: CDY) advises that further to the ASX announcement of 21 May 2019 the Minimum Holding Share Buy-Back has now been completed.

A total of 499,117 fully paid ordinary shares have been bought back at a price of 23 cents per share for a total consideration of \$114,796.91. The proceeds have now been distributed to Shareholders that participated in the Buy-Back and the Shares have been cancelled.

Please find enclosed ASIC Form 484 in relation to the cancellation.

Any Shareholders with a query in relation to the receipt of their proceeds should contact the Company's Share Registry on 1300 288 664 or <u>hello@automic.com.au</u>.

END

Company	Investor Relations & Media
Maria Halasz, CEO	Rebecca Wilson
Cellmid	WE Buchan
T +612 9221 6830	T + 61 417 382 391
info@cellmid.com.au	<u>rwilson@we-buchan.com</u>

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au. Cellmid also has two wholly owned subsidiaries, Lyramid and Kinera, which develop innovative novel therapies and diagnostic tests for fibrotic diseases, cancer and ischemic diseases of the heart. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) globally.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.

Document No. 7EAL59212

Lodgement date/time: 23-05-2019 18:17:15 Reference Id: 126133029

> Form 484 Corporations Act 2001

Change to company details

Company details

Company name CELLMID LIMITED Australian Company Number (ACN) 111 304 119

Lodgement details

Who should ASIC contact if there is a query about this form?

Name AUTOMIC PTY LTD ASIC registered agent number (if applicable)

42686

Signature

This form must be signed by a current officeholder of the company.

I certify that the information in this form is true and complete Name LEE PHILLIP TAMPLIN Capacity Secretary Signature

Date signed 23-05-2019

C1 Cancellation of shares

Reason for cancellation	Shares cancellation details Reason for cancellation				
	ss.257H(3) Share buyback - Minimum holding buy-back only				
	The cancelled shares are listed below:				
	Share class code	Number of shares cancelled	Amount paid (cash or otherwise)		
	ORD	499117	0.23		
	Earliest Date of cancellation	23-05-2019			
		23-05-2019			

C3 Change to share structure

The updated details for this changed share class are shown in the table below.

Share class F code	ull title if not standard	shares	Total amount paid on these shares	Total amount unpaid on these shares
ORD O	RDINARY SHARES	83609475	53719180.33	0.00

Earliest date of 23-05-2019 change